Literature DB >> 19142774

A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.

Robert H Pietrzak1, James Olver, Trevor Norman, Danijela Piskulic, Paul Maruff, Peter J Snyder.   

Abstract

This study examined the criterion and construct validity of a brief computerized cognitive test battery (CogState Schizophrenia Battery) compared to a conventional cognitive test battery recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus. The CogState and MATRICS batteries yielded comparable effect sizes in comparing patients with schizophrenia to healthy controls (Cohen's ds = -1.50 for both batteries). Moderate to large correlations were observed between CogState and MATRICS measures of processing speed, attention/vigilance, working memory, verbal and visual learning, reasoning/problem solving, and social cognition (rs = .56-.79). CogState and MATRICS composite scores also correlated strongly with scores on the University of California at San Diego (UCSD) Performance-Based Skills Assessment (UPSA; rs = .76 and .79, respectively) in patients with schizophrenia. Results of this study suggest that the CogState Schizophrenia Battery provides valid measurement of the cognitive domains nominated by the MATRICS consensus group as being important to consider in the context of pharmacological treatments for cognitive impairment in schizophrenia.

Entities:  

Mesh:

Year:  2009        PMID: 19142774     DOI: 10.1080/13803390802592458

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  44 in total

1.  Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil.

Authors:  R H Pietrzak; P Maruff; P J Snyder
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

Review 2.  Neurocognition: clinical and functional outcomes in schizophrenia.

Authors:  Martin Lepage; Michael Bodnar; Christopher R Bowie
Journal:  Can J Psychiatry       Date:  2014-01       Impact factor: 4.356

3.  Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.

Authors:  Antony D Loebel; Cynthia O Siu; Josephine B Cucchiaro; Andrei A Pikalov; Philip D Harvey
Journal:  CNS Spectr       Date:  2013-12-13       Impact factor: 3.790

4.  Hippocampal volume reduction in female but not male recent abstinent methamphetamine users.

Authors:  Jiang Du; Meina Quan; Wenxu Zhuang; Na Zhong; Haifeng Jiang; David N Kennedy; Amy Harrington; Douglas Ziedonis; Xiaoduo Fan; Min Zhao
Journal:  Behav Brain Res       Date:  2015-04-25       Impact factor: 3.332

5.  The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Authors:  Mario Maj; Jim van Os; Marc De Hert; Wolfgang Gaebel; Silvana Galderisi; Michael F Green; Sinan Guloksuz; Philip D Harvey; Peter B Jones; Dolores Malaspina; Patrick McGorry; Jouko Miettunen; Robin M Murray; Keith H Nuechterlein; Victor Peralta; Graham Thornicroft; Ruud van Winkel; Joseph Ventura
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

Review 6.  Acute and Transient Psychotic Disorders: Newer Understanding.

Authors:  Savita Malhotra; Swapnajeet Sahoo; Srinivas Balachander
Journal:  Curr Psychiatry Rep       Date:  2019-11-04       Impact factor: 5.285

7.  A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia.

Authors:  Akihiro Shiina; Yukihiko Shirayama; Tomihisa Niitsu; Tasuku Hashimoto; Taisuke Yoshida; Tadashi Hasegawa; Tadashi Haraguchi; Nobuhisa Kanahara; Tetsuya Shiraishi; Mihisa Fujisaki; Goro Fukami; Michiko Nakazato; Masaomi Iyo; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-06-24       Impact factor: 3.455

Review 8.  The global cognitive impairment in schizophrenia: consistent over decades and around the world.

Authors:  Jonathan Schaefer; Evan Giangrande; Daniel R Weinberger; Dwight Dickinson
Journal:  Schizophr Res       Date:  2013-08-02       Impact factor: 4.939

9.  Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.

Authors:  Cynthia Z Burton; Lea Vella; Philip D Harvey; Thomas L Patterson; Robert K Heaton; Elizabeth W Twamley
Journal:  Schizophr Res       Date:  2013-03-15       Impact factor: 4.939

Review 10.  Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Authors:  Douglas L Boggs; Jon Carlson; Jose Cortes-Briones; John H Krystal; D Cyril D'Souza
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.